Shots:

• Navigo will use its protein engineering platform to develop a FAP-targeting Affilin molecule then combine it with a therapeutic radioisotope. The companies plan to add the program to ITM’s pipeline for optimal therapeutic effect
• ITM gets exclusive rights to advance the radiolabeled FAP-specific Affilin by clinical testing for multiple cancer indications. The collaboration also includes a non-exclusive license for diagnostic use in radio-imaging
• The agreement will bolster the existing collaboration & combine ITM’s deep expertise in developing targeted radionuclide therapies with Navigo’s Affilin molecules and protein engineering proficiency to develop a new product

Ref: Businesswire | Image: ITM